Etelcalcetide: What we know eight years since its approval Pedro Freitas; Luciano Pereira;

Risk factors for progression in patients with KDOQI stage 3 Chronic Kidney Disease (PROGRESER study) Alberto Martínez-Castelao; José Luis Górriz Teruel; Luis D¿Marco; Enrique Garrigós; Gema Fernández-Fresnedo; Eugenia Espinel Garuz; Secundino Cigarrán Guldris; Jesús Arteaga Coloma; Nicolas Roberto Robles Pérez-Monteoliva; José Rafael Esteban de la Rosa; Luis Javier Nieto Iglesias; Alberto Ortiz Arduán; Juan Francisco Navarro-González;

Experience with PCSK9 inhibitors from a Nephrology unit Verónica Escudero Quesada; Jonay Pantoja Pérez; Cristina Castro Alonso; July Vanessa Osma Capera; Alejandro Valero Antón; Asunción Sancho Calabuig;